Literature DB >> 11705093

Psoriasis of the scalp. Diagnosis and management.

P C van de Kerkhof1, M E Franssen.   

Abstract

Psoriasis of the scalp is a frequently occurring condition affecting approximately 2% of the Western population. The sharply demarcated erythematosquamous lesions with silver-white scaling characterize scalp psoriasis. Quality of life can be seriously reduced by this condition and therefore long term treatment is needed in most patients. Coal tar shampoos, containing 2 to 10% coal tar solution, are effective in scalp psoriasis. However, no double-blind studies are available to support such an assumption. Salicylic acid 5 to 10% has a pronounced keratolytic effect. Salicylic acid should be formulated in an ointment, which can be washed off easily. Crude coal tar is the most effective tar available for the treatment of psoriasis. An important feature of coal tar is its potent efficacy against pruritus. At the scalp, the application of crude coal tar is difficult. Therefore coal tar solution is the most frequently applied tar preparation in scalp psoriasis. Dithranol 0.1 to 3% is manufactured in various formulations. Treatment is initiated at a low concentration and the concentration is increased stepwise until a slight irritation, the feeling of warmth, is reached. In the treatment of scalp psoriasis, cream formulations are used. Imidazole antifungals have been used with success in scalp psoriasis. Overgrowth of the scalp with pityrosporon is a well-known feature of scalp psoriasis and seborrheic dermatitis. In case of resistance to other topical treatments use of a topical or systemic imidazole derivative might be helpful. So far, topical corticosteroids are the most frequently used treatments for psoriasis of the scalp. Corticosteroids inhibit epidermal proliferation, inhibit inflammation and modulate immune functions. Topical corticosteroids are fast acting: within 3 to 4 weeks maximal efficacy is reached. No data are available to support the efficacy and safety of topical corticosteroids during long term use. However, from epidemiologic surveys we know that these treatments are used by the majority of patients for more than 8 weeks. Since 1992 vitamin D3 formulations have been developed for the treatment of psoriasis. Calcipotriol is available in most countries. Tacalcitol is available in Japan and several other countries. Vitamin D3 analogues inhibit epidermal proliferation, enhance cornification and inhibit inflammation. Therefore, vitamin D3 analogues have a substantial antipsoriatic effect. Systemic treatments such as methotrexate, cyclosporine and acitretin are indicated in patients with recalcitrant disease. Management of scalp psoriasis requires long term strategies in order to reach an optimal improvement of the condition, while avoiding the adverse effects associated with the long term use of treatments.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11705093     DOI: 10.2165/00128071-200102030-00005

Source DB:  PubMed          Journal:  Am J Clin Dermatol        ISSN: 1175-0561            Impact factor:   7.403


  22 in total

1.  Use of Topical Coal Tar Foam for the Treatment of Psoriasis in Difficult-to-treat Areas.

Authors:  Joshua A Zeichner
Journal:  J Clin Aesthet Dermatol       Date:  2010-09

2.  A study of the safety and efficacy of calcipotriol and betamethasone dipropionate scalp formulation in the long-term management of scalp psoriasis.

Authors:  T A Luger; F Cambazard; F G Larsen; M Bourcier; G Gupta; F Clonier; P Kidson; N H Shear
Journal:  Dermatology       Date:  2008-09-12       Impact factor: 5.366

3.  Vitamin D analogs in the treatment of psoriasis: Where are we standing and where will we be going?

Authors:  Léa Trémezaygues; Jörg Reichrath
Journal:  Dermatoendocrinol       Date:  2011-07-01

4.  Activated macrophages are essential in a murine model for T cell-mediated chronic psoriasiform skin inflammation.

Authors:  Honglin Wang; Thorsten Peters; Daniel Kess; Anca Sindrilaru; Tsvetelina Oreshkova; Nico Van Rooijen; Athanasios Stratis; Andreas C Renkl; Cord Sunderkötter; Meinhard Wlaschek; Ingo Haase; Karin Scharffetter-Kochanek
Journal:  J Clin Invest       Date:  2006-08       Impact factor: 14.808

5.  Coal tar 2% foam in combination with a superpotent corticosteroid foam for plaque psoriasis: case report and clinical implications.

Authors:  Amylynne J Frankel; Joshua A Zeichner; James Q Del Rosso
Journal:  J Clin Aesthet Dermatol       Date:  2010-10

Review 6.  [Psoriasis capitis and seborrhoic eczema of scalp diseases].

Authors:  M Sticherling
Journal:  Hautarzt       Date:  2017-06       Impact factor: 0.751

Review 7.  Common clinical features and disease mechanisms of psoriasis and psoriatic arthritis.

Authors:  Wendy Myers; Mobolaji Opeola; Alice B Gottlieb
Journal:  Curr Rheumatol Rep       Date:  2004-08       Impact factor: 4.592

8.  Efalizumab in the Treatment of Scalp, Palmoplantar and Nail Psoriasis: Results of a 24-Week Latin American Study.

Authors:  María Denise Takahashi; Edgardo Néstor Chouela; Gladys Leon Dorantes; Ana Maria Roselino; Jesùs Santamaria; Miguel Angel Allevato; Tania Cestari; Maria Eugenia Manzanera de Aillaud; Fernando Miguel Stengel; Daiana Licu
Journal:  Arch Drug Inf       Date:  2010-03

9.  Psoriatic scarring alopecia.

Authors:  Maiana Carneiro Almeida; Ricardo Romiti; Isabella Doche; Neusa Yuriko Sakai Valente; Aline Donati
Journal:  An Bras Dermatol       Date:  2013 Nov-Dec       Impact factor: 1.896

10.  Assessing the Impact of Efalizumab on Nail, Scalp and Palmoplantar Psoriasis and on Quality of Life: Results from a Multicentre, Open-label, Phase IIIb/IV Trial.

Authors:  Andreas Katsambas; Ketty Peris; Gino Vena; Peter Freidmann; Gottfried Wozel; Esteban Daudén; Daiana Licu; Mauro Placchi; Michel De La Brassinne
Journal:  Arch Drug Inf       Date:  2009-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.